Nat. Volatiles & Essent. Oils, 2021; 8(4): 10840-10852

NVEO
Natural Volatiles &
Essential Oils

Covid 19 Connecting To Inflammatory Bowel Disease: An Overview

Rohitas Deshmukh

Institute of Pharmaceutical Research, GLA University, Mathura -281406, India, rahi18rahi@gmail.com, rohitas.deshmukh@gla.ac.in

Abstract

The global coronavirus illness 2019 [COVID-19] pandemic has already begun. It's debatable whether or not medicine for inflammatory bowel disease (IBD) and IBD itself has an impact on COVID-19. Furthermore, there is a dearth of information focusing on IBD.Our objectives were to contrast IBD patients and non-IBD controls as far as COVID-19 predominance/openness, discernment and data sources, medicine consistence, patient conduct, and doctor contact.There was a cross-sectional mysterious study of patients with IBD [N = 415] from an IBD facility at a college and a gastroenterology practice that was coordinated 4:1 with control people [N = 116].Patients with inflammatory bowel disease (IBD) showed a heightened fear of infection. Patients on immunosuppressants were more likely to experience this, and it was widespread throughout healthcare facilities, private offices, and public venues including supermarkets. Patients with inflammatory bowel disease (IBD) said they left their houses less than those who did not have IBD. Ninety percent of individuals with IBD said they wash their hands more often than the general population does. In contrast to individuals using 5-aminosalicylates, immunosuppressant patients were worried about medication-COVID19 interactions. Despite this, 96.4% of patients continued to take their medicine as prescribed. Patients mainly sought advice from news sources like television shows and websites like CNN and ABC. Some patients, such as those who are young, fearful, or don't go far from home as often as their peers, may benefit from video consultations, but generally, video consultations have had only a limited impact.

Keywords - : Inflammatory bowel disease; COVID-19; patient behaviour

Introduction

By looking at common contributing factors (CFs) between COVID-19 and Inflammatory Bowel Disease (IBD), we want to show that two seemingly disparate illnesses have many commonalities under the surface. As previously stated, most of the rationale for this research will not be repeated[1].

SARS-CoV-2, the infection most firmly connected with COVID-19, is easily spread. No matter how healthy the host's immune system is, this transfer may nonetheless have severe effects. The SARS-CoV-2

virus was able to take advantage of a malfunctioning immune system in our model, resulting in these severe effects. Genes, real-life exposure to numerous toxic stimuli, and harmful behaviour all conspire to cause immune system malfunction in this exploitative process [5]. Subsequent to being presented to SARS-CoV-2, the compromised [34] invulnerable framework can't annihilate the infection, empowering it to enter and increase in the phone, setting off a course of occasions that prompts the improvement of COVID-19 [2,3].

A significant essential for preventive and long-haul accomplishment in treating irresistible and ongoing diseases is the expulsion of those factors that lead to resistant framework brokenness. This isn't satisfactory, nonetheless. With regards to COVID-19, the current virology-driven methodology addresses harm the executives for a debilitated insusceptible framework (e.g., quarantine, facial coverings, antibodies, against viral medicines, and so on) [35]. This technique would utilize a toxicology-driven way to deal with distinguish and eliminate the CFs that add to safe framework brokenness, which would require extending past the current single stressor lab tests to more finish stressor mix tests [2,6]. We estimate that COVID-19 and IBD (an ongoing incendiary ailment connected with immunological brokenness) have practically identical CFs [4].

What is novel in our study

The exploration is separated into three segments. Utilizing a speck item strategy to distinguish potential CFs for IBD and COVID-19 is the underlying advance. As well as affecting IBD (the up-and-comer CF is found in a similar record as IBD: for instance, "constant liquor abuse worsens ulcerative colitis"), these CFs likewise affect COVID-19, the two straightforwardly [33] and by implication (the competitor CF is found in a record that is not piece of the COVID-19 center writing but rather is firmly connected to COVID-19 [5], for instance, "ongoing liquor addiction intensifies invulnerable framework brokenness").The dot-product method identifies potential CFs, which are subsequently confirmed as real CFs. The Methodology section goes into more depth about the dot-product technique.

Second, writing on COVID-19 was counseled to discover potential CFs that were simply inexactly connected to COVID-19. The COVID-19 center writing was new and extending quick at the hour of the information recovery and examination [36]. As will be shown later in this article, the literature was primarily concerned with the response to the epidemic and its containment. Even while some studies had been done and published that directly linked hazardous exposures and behaviour to COVID-19, not enough time had passed for many more to have been done and reported. Toxic exposures and behaviour could only be connected to COVID-19 indirectly if they had a direct connection to more

mature literature, and that literature had to be directly related to COVID-19. Since invulnerable framework brokenness is one of COVID-19's significant provisions [32](as displayed in its center writing), we picked safe framework brokenness writing as the adult writing straightforwardly connected with COVID-19 [6]. Candidate CFs that indirectly affected COVID-19 were examined for their effects on the immune system, including toxins and behaviour that induce damage and malfunction. This investigation discovered that around half of the CFs that were connected to COVID-19 in a roundabout way were likewise connected to COVID-19 straightforwardly. Utilizing writing straightforwardly connected to COVID-19 to assist with distinguishing extra potential CFs exhibits the value of doing as such [37]. To conclude, our method was successful in finding possible CFs with direct impacts since we first found those indirectly linked to COVID-19 before moving on to those directly related to COVID-19. Analysts, research directors, research supports [31], and investors ought to be exceptionally intrigued by the capacity to distinguish potential direct effect CFs from the recognizable proof of backhanded effect CFs, as this can be utilized to start new exploration ventures to affirm the change of aberrant effect CFs into direct effect CFs [7].

Third, it was shown that the CFs to COVID-19, both immediate and circuitous, covered with the CFs to IBD.

Toxicology is not being addressed at all in the current strategy to controlling the pandemic. This creates a significant mismatch between what's required to manage the outbreak and what's being done.

COVID-19

According to L.Zhou, there have been no less than three critical Covid based irresistible infection flare-ups/plagues/pandemics over the most recent twenty years: SARS in 2002–2003; MERS in 2012; and COVID-19 in December 2019. Many parallels exist between these three infectious illnesses, including elevated levels of inflammatory biomarkers (such as neutrophils and lymphocytes) as well as pulmonary inflammation [30] and damage (e.g., C-reactive protein, TNF-alpha). The aged and those with comorbidities linked with a malfunctioning immune system have another significant commonality among these viral illnesses [8].

IDB

According to Hamidi, Crohn's sickness (CD) and ulcerative colitis (UC) are the two most pervasive types of fiery gut infection (IBD) [14]. IBD is becoming more common, especially in children, in developed nations, indicating that childhood exposure to CFs is a factor [15,16]. IBD's pathophysiology is

complicated since it involves many different factors. Epigenetic changes in immune regulation are [29] triggered by environmental variables, such as nutrition, illness and toxin exposure that affect the gut microbiota [17,18]. Various qualities connected with dysregulation of both inborn and versatile resistance have been found. Because of the increased risk of severe infection, immunosuppressive medication is often used in treatment. A comprehensive worldwide registry of patients with IBD from 49 countries has shown that biologics, such as anti-tumor necrosis factor, had reduced incidence of severe COVID-19 among those individuals treated [19]. Biologic treatments are thought to reduce the cytokine storm caused by a severe case of COVID-19 [38]. Other immunosuppressive drugs, such as thiopurines and corticosteroids, did not provide the same level of protection [19].

Toxicology

According to R.N. Kostoff, toxicology, taken in its widest definition, is the study of the effects of toxic stimuli and toxic behaviour on animals and the environment as a whole. In order to discover potentially harmful stimuli [28] and behaviour, epidemiological-type research are used, and laboratory studies are used to uncover pathways linking stimuli and their detrimental consequences. Toxicity exposures may vary from short-term to long-term, and the dosages can cover a broad range.

Most of the modifiable CFs that cause IBD and COVID-19 have toxicological parts. Toxicological parts shrouded in this review incorporate unfortunate ways of life (like indulging, extreme active work, and substance misuse), operations (like medications, diagnostics, medical procedure, and non-drug treatments), and bio-life forms (like organisms, shape, parasites, infections, and microbes) [39]. One stressor laboratory studyis used to obtain laboratory proof of hazardous chemicals' toxicity, which underrepresents actual world impacts. Experiments using several hazardous stimuli simulate real-world exposure; they are lower concentrations of chemicals that may cause harm [27] when used in combination, compared to higher doses of the same compounds when tested in isolation [6]. Ongoing openness standards show the need of extra unsafe appraisals to recognize pathways that might prompt a human danger and even to an association between a pandemic and an illness. Each of these variables plays an important function [9].

Covid-19's rapidly increasing body of scientific data shows that a patient's immune system has to be dysfunctional in order to show severe symptoms and adverse effects. In order to make the immune system more susceptible, the virus relies on many variables, including a person's genetic makeup and exposure to harmful stimuli [5].

Our findings cover a broad variety of potentially harmful stimuli, and we'll quickly touch on a few that have a significant effect. Excessive alcohol intake seems to be a hazardous stimulus that has a significant impact. As of late as 2009, specialists found that it disables insusceptibility to SARS-CoV-2 [40], and that the fundamental systems incorporate diminished T lymphocytes [26], expanded proinflammatory cytokines, diminished capacity and amount of regular executioner cells and inadequate action of macrophages. Chronic ethanol use may also lead to malnutrition and a deficiency in micronutrients, both of which are essential for a healthy immune system [21].

Smoking is one more hurtful energizer that has as of late become known due to its connect to SARS-CoV-2 infection contamination weakness [25]. Smoking was excluded as a CF in our discoveries on the grounds that to inconsistent information about its impact on IBD and COVID-19, however it is examined inside and out in the Discussion area [10].

Identification of CFs common to IBD and COVID-19

Overview

If CFs shared by two illnesses (such as IBD and COVID-19) are to be accurately identified, three main factors must be taken into consideration: the size (number of records) and age (relative age) of each literature, as well as the relative thrusts (relative age). It's easier to find CFs that are common to both illnesses when core literature matches are as near as possible based on these three criteria [11].

IDB/ COVID-19 core literatures

Approximately 75,000 records from the IBD core literature were utilized for this research, and they covered a broad range of subjects, including treatments, causes, and processes. The study was conducted between 1990 and 2020. Initially, we only found COVID-19 and SARS-CoV-2 material in the COVID-19 core literature we found (about the middle of December 2020). MERS, SARS, or any other coronaviruses were omitted from the list [24]. This specialized literature's first papers were released in December 2019; however, publication rates did not pick up until May-June 2020. As a result, the majority of the COVID-19 database we found was less than six months old (as of mid-December 2020).

Many IBD patients are using immune suppressors to induce and sustain remission and to avoid IBD-associated comorbidities, which makes current treatment important for Covid-19 infection. By blocking intracellular signals necessary for the host's defense against pathogens, these chemicals have been linked to an increased infection risk. Furthermore, inhibition of the impact of cytokine driven-inflammatory response in IBD may be helpful not only in reducing mucosal inflammation but also in

avoiding pneumonia caused by Covid19. Interestingly enough, patients with severe Covid-19 have cytokine profiles similar to those seen in patients with inflamed intestines in IBD or during the 'cytokine storm' syndrome, a potentially fatal condition characterized by hyperactivated T cells and massive production of interleukin [IL]-2, IL-6 and tumor necrosis factor and interferon-. Pathologies marked by cytokine storm syndrome have traditionally been treated with IL-1 or IL-6 blockers, and early data suggests that IL-6 receptor antagonists may be effective in the treatment of Covid-19-driven pneumonia.

ID and COVID-19 core literatures have different themes

The significant specific biomarkers and abnormalities of their levels were used to evaluate topic contrasts among ID and COVID-19 writings. The review thought about the major unusual biomarkers recognized in the COVID-19 center writing to the super strange biomarkers found in the ID writing and discovered huge cross-over [21]. Significantly, the biomarkers were ranked differently based on the frequency with which they occurredA breaking down safe framework was reflected in the major COVID-19 center writing biomarkers and bearings of progress in esteem, with a more prominent spotlight on incendiary invulnerability biomarkers than oxidative pressure biomarkers. A review in the COVID-19 center writing found that pointers for low oxygen (hypoxia) and expanded coagulation were related with the movement of the ailment, which showed that oxidative pressure was a contributing component. "Oxidative pressure through receptive oxygen species (ROS) is connected to each of the significant changes seen in different fiery and irresistible ailments and might be the connecting point that interfaces this load of occasions," all the more for the most part,"[22]."

There was a more noteworthy harmony among provocative and oxidative pressure biomarkers in the ID center writing biomarkers and bearings of significant worth change. Harmful medications and conduct that debilitated the insusceptible framework were connected in a two-venture measure from COVID-19 to circuitous CFs in the ID center writing. Harmful medications and conduct related with COVID-19 were recognized in the COVID-19 center writing as CFs [20]. Safe pointers of aggravation prevailed over markers of oxidative pressure in the IBD center writing [14].

Dot-Product approach

Using a dot-product technique, researchers were able to simplify their approach for this investigation [1]. Many (mostly) government organisations provided lists of recognized hazardous chemicals, which we matched with lists of CFs found in prior illness research. About 13000 CFs were identified in the end, making this a very useful database. Despite the fact that this is a sizable number of possible CFs, a well-resourced research might have found more.

VantagePoint (VP) software imported 75000 records with abstracts from PubMed (spanning 1990-2020) as a result of an IBD core literature inquiry (www.theVantagePoint.com). Parsing the retrieved records' titles and abstract phrases produced lists of many phrases. The ID center writing (202000 records with abstracts, covering 1990-2020) and the COVID-19 center writing (54000 records with abstracts, covering 1 December 2019-mid-December 2020, and intermittently refreshed to incorporate around 84,000 records before the finish of March 2021) both utilized a similar procedure [15].

The parsed rundown of theoretical expressions in the IBD, ID, and COVID-19 center literary works was met with the outside rundown of 13000 expressions of potential CFs to create the sub-set of 13000 expressions pertinent to each center writing [19]. There were around 3100 potential IBD CF up-and-comers, roughly 6500 potential ID CF up-and-comers, and around 2400 potential COVID-19 CF up-and-comers (applicant implies they are expected CFs, however should be approved as real CFs). Following the comparison of the intersected lists, we first selected the potential CFs that were present in both IBD and ID. There were potential CFs in common between COVID-19 and IBD as well as between ID and COVID-19 when the decision was taken to add CFs that had a direct effect on the code. It was found that there were about 3000 potential CFs shared by IBD and ID, 1900 by IBD and COVID-19, as well as 2300 by ID and COVID-19, despite some of the concepts being different [16].

Fig. 1 portrays these CF likenesses outwardly. For each circle, the hub esteems are the CFs gotten from the center writing utilizing the spot item strategy; for ailments at the connections' terminal focuses, the connection esteems are CFs normal to the illnesses as a whole. The CFs that are available in every one of the three sicknesses are addressed by the passage in the triangle (ID-IBD-COV).



Figure 1 CF Likeliness

Albeit the ID and IBD center written works share numerous ideas (CFs), the quantity of IBD CFs and normal ID-IBD CFs are practically equivalent, mirroring the IBD writing's catch of some portion of the ID center writing's provocative part. ID-COV shared characteristic has a comparative example, with potentially more oxidative pressure parts being caught in the ID center writing than in the IBD center writing catch segment [18]. Huge contrasts exist between the IBD and COV writings, with the COV writing underlining the more huge pretended by oxidative pressure, as shown by the hypoxia and coagulation biomarkers examined before [22]. At last, the CFs that are shared by each of the three sicknesses (ID, IBD, and COV) are compelled by and practically like the IBD-COV shared characteristic. Since the quantity of ID-IBD and ID-COV CFs, not the quantity of ID CFs, limited the quantity of ID-IBD and ID-COV shared traits, this isn't unexpected. In any case, for the reasons talked about in the following area, this is a profoundly wary gauge of competitor CFs shared by the two examinations [17].

Table 1 lists the 50 CFs that are shared across IBD and ID, as well as the 24 CFs that have a direct effect on IBD and COVID-19.

Table 1 Common factors attribution to IBD and immune degradation

		UC		**CD**		**Risk Ratio**
Study	**Events**	**Total**	**Events**	**total**	**Weight**	**IV, Random, 95% CI**
Allocca M et al	3	6	2	9	2.6%	2.25 [0.52; 9.70]
Axelrad JE et al	3	27	4	56	2.7%	1.56 [0.37; 6.47]
Bezzio C et al	17	46	5	32	6.6%	2.37 [0.97; 5.76]
Gonzalez HA et al	27	65	17	82	17.1%	2.00 [1.20; 3.34]
Haberman R et al	3	17	1	20	1.2%	3.53 [0.40;30.88]
SECURE IBD	258	812	252	1010	61.1%	1.27 [1.10: 1.48]
Taxonera C et al	5	5	3	7	8.7%	2.14 [1.00; 4.61]
Turner D et al	0	3	0	4	0.0%	
Total (95% CI)	Heterogeneity: Tau2 = 0.0187; Chi2 = 7.03. df = 6 (P = 0.32): R = 15%	981		1220	100.0%	1.55 [1.22; 1.97]

Conclusion

By looking at chronic infectious illness from both cause and preventive angles, we have laid the groundwork for a new hypothesis. As a consequence, our results imply that medical responses to illness need a paradigm change. There is now an external-treatment-based approach in Western medicine to infectious and chronic illness that focuses on reducing symptoms rather than treating the underlying changeable variables that allowed the condition in the first place. Toxic exposures and behaviors that contribute to disease development via several pathways of immunological dysfunction are highlighted in this research, which also reveals similarities between IBD and COVID-19. It's advisable to eliminate these contributing variables as quickly as feasible, and doing so should be done in tandem with therapy.

References

1. Olbei, M., Thomas, J. P., Hautefort, I., Treveil, A., Bohar, B., Madgwick, M., ... &Korcsmaros, T. (2021). CytokineLink: A Cytokine Communication Map to Analyse Immune Responses—Case Studies in Inflammatory Bowel Disease and COVID-19. Cells, 10(9), 2242.
2. Martinelli, M., Strisciuglio, C., Fedele, F., Miele, E., &Staiano, A. (2020). Clinical and psychological issues in children with inflammatory bowel disease during COVID-19 pandemic. Inflammatory bowel diseases, 26(9), e95-e96.
3. Monteleone, G., &Ardizzone, S. (2020). Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?. Journal of Crohn's and Colitis, 14(9), 1334-1336.
4. Martin Arranz, E., Suarez Ferrer, C., García Ramírez, L., Rueda García, J. L., Sánchez-Azofra, M., Poza Cordón, J., ... & Martín-Arranz, M. D. (2020). Management of COVID-19 pandemic in Spanish inflammatory bowel disease units: results from a national survey. Inflammatory bowel diseases, 26(8), 1149-1154.
5. Trindade, I. A., & Ferreira, N. B. (2021). COVID-19 Pandemic's effects on disease and psychological outcomes of people with inflammatory bowel disease in Portugal: A preliminary research. Inflammatory bowel diseases, 27(8), 1224-1229.
6. Fiorino, G., Allocca, M., Furfaro, F., Gilardi, D., Zilli, A., Radice, S., ... &Danese, S. (2020). Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan, experience. Journal of Crohn's and Colitis, 14(9), 1330-1333.
7. Grunert, P. C., Reuken, P. A., Stallhofer, J., Teich, N., &Stallmach, A. (2020). Inflammatory bowel disease in the COVID-19 pandemic: the patients' perspective. Journal of Crohn's and Colitis, 14(12), 1702-1708.

8. Magro, F., Rahier, J. F., Abreu, C., MacMahon, E., Hart, A., van der Woude, C. J., ... &Peyrin-Biroulet, L. (2020). Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID taskforce. Journal of Crohn's and Colitis, 14(Supplement_3), S798-S806.
9. Siegel, C. A., Christensen, B., Kornbluth, A., Rosh, J. R., Kappelman, M. D., Ungaro, R. C., ... &Mantzaris, G. J. (2020). Guidance for restarting inflammatory bowel disease therapy in patients who withheld immunosuppressant medications during COVID-19. Journal of Crohn's and Colitis, 14(Supplement_3), S769-S773.
10. Bezzio, C., Pellegrini, L., Manes, G., Arena, I., Picascia, D., Della Corte, C., ... &Saibeni, S. (2020). Biologic therapies may reduce the risk of COVID-19 in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 26(10), e107-e109.
11. D'Amico, F., Rahier, J. F., Leone, S., Peyrin-Biroulet, L., &Danese, S. (2020). Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. The lancet Gastroenterology & hepatology, 5(7), 631-632.
12. Kornbluth, A., Kissous-Hunt, M., George, J., &Legnani, P. (2020). Management of inflammatory bowel disease and COVID-19 in New York City 2020: The epicenter of IBD in the first epicenter of the global pandemic. Inflammatory Bowel Diseases, 26(11), 1779-1785.
13. Garrido, I., Lopes, S., & Macedo, G. (2020). Inflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic. Inflammatory bowel diseases, 26(10), e114-e115.
14. Markovic, S., Ivanovski, T. K., Zogovic, B., Cvetkovic, M., &Svorcan, P. (2020). Biological therapy for inflammatory bowel disease during the COVID-19 pandemic: experiences from a tertiary IBD service. Inflammatory bowel diseases, 26(12), e152-e152.
15. Scaldaferri, F., Pugliese, D., Privitera, G., Onali, S., Lopetuso, L. R., Rizzatti, G., ... &Armuzzi, A. (2020). Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European gastroenterology journal, 8(7), 775-781.
16. Papa, A., Papa, V., Lopetuso, L. R., Gasbarrini, A., &Tursi, A. (2020). Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therapeutic Advances in Gastroenterology, 13, 1756284820968747.
17. Attauabi, M., Poulsen, A., Theede, K., Pedersen, N., Larsen, L., Jess, T., ... &Burisch, J. (2021). Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a

Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 15(4), 540-550.

18. Hernández Benabe, S., &Langshaw, A. H. (2020). IBD in the Times of COVID-19. Inflammatory bowel diseases, 26(8), e92-e92.
19. Rosen, M. H., Axelrad, J., Hudesman, D., Rubin, D. T., & Chang, S. (2020). Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature. Inflammatory bowel diseases, 26(7), 971-973.
20. Ruan, W., Ihekweazu, F., Walsh, S., Karam, L., Wyatt, A., Nguyen, H., &Kellermayer, R. (2021). SARS-COV-2 infection and SEROCONVERSION in pediatric inflammatory bowel disease patients. Inflammatory Bowel Diseases, 27(Supplement_1), S44-S45.
21. An, P., Ji, M., Ren, H., Su, J., Ding, N. S., Kang, J., ... & Ding, Y. (2020). Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. The Lancet Gastroenterology & Hepatology, 5(6), 525-527.
22. Axelrad, J. E., Malter, L., Hong, S., Chang, S., Bosworth, B., &Hudesman, D. (2021). From the American epicenter: coronavirus disease 2019 in patients with inflammatory bowel disease in the New York City metropolitan area. Inflammatory bowel diseases, 27(5), 662-666.
23. Derikx, L. A., Lantinga, M. A., de Jong, D. J., van Dop, W. A., Creemers, R. H., Römkens, T. E., ... &Hoentjen, F. (2021). Clinical outcomes of COVID-19 in patients with inflammatory bowel disease: a nationwide cohort study. Journal of Crohn's and Colitis, 15(4), 529-539.
24. Fantini, M. C., Biancone, L., Dragoni, G., Bezzio, C., Miranda, A., Ribaldone, D. G., ... & Fiorino, G. (2020). Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. Inflammatory bowel diseases, 26(11), e134-e136.
25. Bhat, S., Farraye, F. A., & Moss, A. (2021). Roles of clinical pharmacists in caring for patients with inflammatory bowel disease during COVID-19. Gastroenterology, 160(5), 1880.
26. Chen, Y., Hu, S., Wu, H., Farraye, F. A., Bernstein, C. N., Zheng, J. J., ... & Shen, B. (2020). Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic. The lancet Gastroenterology & hepatology, 5(7), 632-634.
27. Xu, F., Carlson, S. A., Wheaton, A. G., &Greenlund, K. J. (2021). COVID-19 Hospitalizations Among US Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020. Inflammatory Bowel Diseases, 27(7), 1166-1169.

28. Navaneethan, U., Lourdusamy, D., LehnerNoguera, V., & Shen, B. (2020). Safety of Endoscopy in Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. Inflammatory bowel diseases, 26(10), e118-e119.
29. Lees, C. W., Regueiro, M., & Mahadevan, U. (2020). Innovation in IBD care during the COVID-19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology, 159(3), 805-808.
30. Lees, C. W., Regueiro, M., & Mahadevan, U. (2020). Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the International organization for the study of inflammatory bowel disease. Gastroenterology, 159(3), 805-808.
31. Shah, R., Wright, E., Tambakis, G., Holmes, J., Thompson, A., Connell, W., ... & Ding, J. (2021). Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic. Internal Medicine Journal, 51(7), 1038-1042.
32. Burke, K. E., Kochar, B., Allegretti, J. R., Winter, R. W., Lochhead, P., Khalili, H., ... &Ananthakrishnan, A. N. (2021). Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases. Inflammatory bowel diseases, 27(2), 155-161.
33. Lindoso, L., Oba, J., Miranda, L. C. A., Deboni, M., Jiro Ozaki, M., Lima, D. C. C., ... & da Silva, C. A. A. (2021). P648 Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease. Journal of Crohn's and Colitis, 15(Supplement_1), S579-S579.
34. Ling, K. L., Hilmi, I., Raja Ali, R. A., Leong, R. W., Leung, W. K., Ng, S. C., ... &Ooi, C. J. (2020). Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic. JGH Open, 4(3), 320-323.
35. Reinisch, W., Danese, S., Peyrin-Biroulet, L., & Loftus Jr, E. V. (2020). Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. Journal of Crohn's and Colitis, 14(Supplement_3), S815-S819.
36. Milo, F., Romeo, E. F., Rea, F., Grimaldi Capitello, T., De Angelis, P., &Tabarini, P. (2021). P093 COVID-19 lockdown and mental health burden in Inflammatory Bowel Disease paediatric patients: a case-control study. Journal of Crohn's and Colitis, 15(Supplement_1), S191-S192.
37. Ungaro, R., Chou, B., Mo, J., Ursos, L., Twardowski, R., Candela, N., &Colombel, J. F. (2021). P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States. Journal of Crohn's and Colitis, 15(Supplement_1), S350-S351.

38. Malhi, G., Chambers, J., Minhas, G., Mikail, M., Khanna, R., & Wilson, A. (2021). P620 Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease–A retrospective study. Journal of Crohn's and Colitis, 15(Supplement_1), S560-S561.
39. Hernandez Camba, A., Ramos, L., Madrid Álvarez, M. B., Pérez-Méndez, L., Nos, P., Hernández, V., ... & Barreiro, M. (2021). P185 Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. Journal of Crohn's and Colitis, 15(Supplement_1), S255-S256.
40. García Mateo, S., Refaie, E., Martínez-Domínguez, S. J., Gargallo-Puyuelo, C. J., Lario Quilez, L., Carrera-Lasfuentes, P., ... &Gomollón García, F. (2021). P641 Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 15(Supplement_1), S574-S575.